Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

NCT00607919

Attention Deficit Hyperactivity Disorder Dyslexia

COMPLETED PHASE4

Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)

NCT00191906

Attention Deficit Hyperactivity Disorder Reading Disorder

COMPLETED PHASE4

Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD

NCT00191048

Attention-Deficit/Hyperactivity Disorder Comorbid Dyslexia

COMPLETED PHASE4

Effects of Atomoxetine in Mild Cognitive Impairment

NCT01522404

Mild Cognitive Impairment

COMPLETED PHASE2

Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes

NCT00510276

Attention Deficit Hyperactivity Disorder

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, placebo-controlled, double-blind, single site study that uses an fMRI measurement to assess brain activation during attention and reading tasks and the effects of atomoxetine in reducing symptoms of ADHD in participants with ADHD and comorbid dyslexia. Similar assessments are performed in two additional groups of participants with ADHD only and dyslexia only to determine to what extent symptomatic change in the comorbid ADHD \& dyslexia is achieved independently by atomoxetine effects on either condition. A healthy control group of non-ADHD, non-dyslexia subjects (20) will be included to monitor practice effects \& effects of treatment that may be interpreted as normal maturation. The healthy control group will not be treated with any study medications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Attention Deficit Hyperactivity Disorder Dyslexia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atomoxetine

Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks (study period II). Participants who complete the study period II will be re-randomized in the study period III of 16-week duration to assess maintenance of benefit following discontinuation of treatment with atomoxetine. Participants assigned to atomoxetine during the study period II will be re-randomized to either atomoxetine or placebo whereas participants previously assigned to placebo will receive atomoxetine.

Group Type EXPERIMENTAL

Atomoxetine

Intervention Type DRUG

Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks

Placebo

Placebo will be packaged in the same way as active comparator to enforce double-blind study design

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

oral, daily, for 16 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atomoxetine

Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks

Intervention Type DRUG

Placebo

oral, daily, for 16 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY139603

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants in the ADHD-only or ADHD+dyslexia groups must meet DSM-IV-TR criteria for ADHD
* Participants in the dyslexia-alone group or ADHD+dyslexia groups must meet criteria for dyslexia
* Participants must achieve a score of 80 or more on the Full Scale Intelligence Quotient
* Child or adolescent participants must be 10 to 16 years old
* Must be able to communicate in English
* Must be able to swallow capsules
* Be reliable to keep appointments for clinic visits \& all related tests
* Participants for healthy control group do not meet DSM-IV-TR criteria for ADHD and/or dyslexia
* Participants for healthy control group must achieve a score of at least 80 but not \>120 on the Full Scale Intelligence Quotient

Exclusion Criteria

* Participants who weigh less than 25.1 kilogram (kg) or greater than 70 kg.
* Participants with severe allergies to more than 1 class of medications or who have had multiple adverse drug reactions
* Participants with prior diagnosis of bipolar I or bipolar II disorder or psychosis
* Participants with documented history of autism, Asperger's syndrome, or pervasive developmental disorder
* Females who are pregnant or breastfeeding
* Participants treated with atomoxetine at a therapeutic dose (1.2 mg/kg/day) for at least 4 to 6 weeks

Minimum Eligible Age

10 Years

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No